Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity.

Dong M, Pinon DI, Miller LJ.

Regul Pept. 2013 Jan 10;180:5-11. doi: 10.1016/j.regpep.2012.10.001. Epub 2012 Nov 8.

2.

Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery.

Harikumar KG, Wootten D, Pinon DI, Koole C, Ball AM, Furness SG, Graham B, Dong M, Christopoulos A, Miller LJ, Sexton PM.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18607-12. doi: 10.1073/pnas.1205227109. Epub 2012 Oct 22.

3.

Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping.

Dong M, Xu X, Ball AM, Makhoul JA, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ.

FASEB J. 2012 Dec;26(12):5092-105. doi: 10.1096/fj.12-212399. Epub 2012 Sep 10.

4.

Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket.

Dong M, Pinon DI, Miller LJ.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):638-41. doi: 10.1016/j.bmcl.2011.10.065. Epub 2011 Oct 25.

5.

Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist.

Dong M, Te JA, Xu X, Wang J, Pinon DI, Storjohann L, Bordner AJ, Miller LJ.

Biochemistry. 2011 Sep 27;50(38):8181-92. doi: 10.1021/bi2008036. Epub 2011 Aug 30.

6.

Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore.

Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM, Abagyan R, Miller LJ.

J Biol Chem. 2011 Jul 8;286(27):23888-99. doi: 10.1074/jbc.M111.245969. Epub 2011 May 12.

7.

Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.

Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, Dong M.

J Biol Chem. 2011 May 6;286(18):15895-907. doi: 10.1074/jbc.M110.217901. Epub 2011 Mar 16.

8.

Importance of each residue within secretin for receptor binding and biological activity.

Dong M, Le A, Te JA, Pinon DI, Bordner AJ, Miller LJ.

Biochemistry. 2011 Apr 12;50(14):2983-93. doi: 10.1021/bi200133u. Epub 2011 Mar 21.

9.

Elucidation of the active conformation of the amino terminus of receptor-bound secretin using intramolecular disulfide bond constraints.

Dong M, Pinon DI, Bordner AJ, Miller LJ.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6040-4. doi: 10.1016/j.bmcl.2010.08.062. Epub 2010 Aug 15.

10.

Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.

Chen Q, Pinon DI, Miller LJ, Dong M.

J Biol Chem. 2010 Aug 6;285(32):24508-18. doi: 10.1074/jbc.M110.135749. Epub 2010 Jun 7.

11.

Refinement of the pharmacophore of an agonist ligand of the secretin receptor using conformationally constrained cyclic hexapeptides.

Dong M, Narang P, Pinon DI, Bordner AJ, Miller LJ.

Peptides. 2010 Jun;31(6):1094-8. doi: 10.1016/j.peptides.2010.02.024. Epub 2010 Mar 7.

12.

Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment.

Dong M, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ.

J Biol Chem. 2010 Mar 26;285(13):9919-31. doi: 10.1074/jbc.M109.089730. Epub 2010 Jan 25.

13.

Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes.

Chen Q, Pinon DI, Miller LJ, Dong M.

J Biol Chem. 2009 Dec 4;284(49):34135-44. doi: 10.1074/jbc.M109.038109. Epub 2009 Oct 8.

14.
15.

Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Harikumar KG, Gao F, Pinon DI, Miller LJ.

Biochemistry. 2008 Sep 9;47(36):9574-81. doi: 10.1021/bi800734w. Epub 2008 Aug 13.

16.

Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding.

Dong M, Lam PC, Pinon DI, Sexton PM, Abagyan R, Miller LJ.

Mol Pharmacol. 2008 Aug;74(2):413-22. doi: 10.1124/mol.108.047209. Epub 2008 May 8.

17.

Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptides.

Dong M, Pinon DI, Miller LJ.

J Mol Neurosci. 2008 Nov;36(1-3):254-9. doi: 10.1007/s12031-008-9058-6. Epub 2008 Apr 12.

18.

Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors.

Dong M, Gao F, Pinon DI, Miller LJ.

Mol Endocrinol. 2008 Jun;22(6):1489-99. doi: 10.1210/me.2008-0025. Epub 2008 Mar 27.

19.
20.

Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor.

Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ.

Mol Pharmacol. 2007 Aug;72(2):280-90. Epub 2007 May 2.

PMID:
17475809
21.

Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.

Harikumar KG, Dong M, Cheng Z, Pinon DI, Lybrand TP, Miller LJ.

Biochemistry. 2006 Dec 12;45(49):14706-16.

23.

Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.

Harikumar KG, Pinon DI, Miller LJ.

Biosci Rep. 2006 Apr;26(2):89-100.

PMID:
16779661
24.

Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors.

Dong M, Pinon DI, Asmann YW, Miller LJ.

Mol Pharmacol. 2006 Jul;70(1):206-13. Epub 2006 Mar 10.

PMID:
16531505
25.

Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling.

Dong M, Hosohata K, Pinon DI, Muthukumaraswamy N, Miller LJ.

Mol Endocrinol. 2006 Jul;20(7):1688-98. Epub 2006 Mar 2.

PMID:
16513792
27.
28.

Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.

Dong M, Hadac EM, Pinon DI, Miller LJ.

Mol Pharmacol. 2005 Jun;67(6):1892-900. Epub 2005 Mar 17.

PMID:
15774770
29.
30.

Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog.

Matsuura B, Dong M, Coulie B, Pinon DI, Miller LJ.

J Pharmacol Exp Ther. 2005 Jun;313(3):1101-8. Epub 2005 Jan 26.

PMID:
15677347
31.

Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.

Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ.

J Biol Chem. 2005 Jan 14;280(2):1044-50. Epub 2004 Nov 1.

32.
33.
34.

Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.

Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.

Mol Pharmacol. 2004 Jan;65(1):28-35.

PMID:
14722234
35.

Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor.

Dong M, Li Z, Pinon DI, Lybrand TP, Miller LJ.

J Biol Chem. 2004 Jan 23;279(4):2894-903. Epub 2003 Oct 30.

38.

Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor.

Zang M, Dong M, Pinon DI, Ding XQ, Hadac EM, Li Z, Lybrand TP, Miller LJ.

Mol Pharmacol. 2003 May;63(5):993-1001. Erratum in: Mol Pharmacol. 2003 Ju;;64(1):193.

PMID:
12695527
40.

Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus.

Dong M, Zang M, Pinon DI, Li Z, Lybrand TP, Miller LJ.

Mol Endocrinol. 2002 Nov;16(11):2490-501.

PMID:
12403838
41.

Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.

Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ.

Mol Pharmacol. 2002 May;61(5):1041-52.

PMID:
11961122
42.

Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.

Harikumar KG, Pinon DI, Wessels WS, Prendergast FG, Miller LJ.

J Biol Chem. 2002 May 24;277(21):18552-60. Epub 2002 Mar 13.

43.

Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling.

Coulie B, Matsuura B, Dong M, Hadac EM, Pinon DI, Feighner SD, Howard AD, Miller LJ.

J Biol Chem. 2001 Sep 21;276(38):35518-22. Epub 2001 Jul 18.

44.

Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.

Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ.

J Biol Chem. 2001 Feb 9;276(6):4236-44. Epub 2000 Oct 24.

45.

Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.

Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ.

J Pharmacol Exp Ther. 2000 Nov;295(2):682-8.

PMID:
11046106
46.

Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor.

Dong M, Asmann YW, Zang M, Pinon DI, Miller LJ.

J Biol Chem. 2000 Aug 25;275(34):26032-9.

47.
49.

Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist.

Roettger BF, Pinon DI, Burghardt TP, Miller LJ.

Am J Physiol. 1999 Mar;276(3):C539-47. doi: 10.1152/ajpcell.1999.276.3.C539.

PMID:
10069980

Supplemental Content

Loading ...
Support Center